| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,800,000 |
| Market
Cap: |
168.90(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.4 - $9.48 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kodiak Sciences is a biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer conjugate for the treatment in retinal vascular diseases including wet age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusion. Co.'s pipeline, including product candidates KSI-501 and KSI-601, are used for other needs in retina such as dry AMD and glaucoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,379,445 |
| Total Buy Value |
$0 |
$0 |
$0 |
$9,508,745 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
9 |
| Total Shares Sold |
0 |
0 |
7,587 |
15,417 |
| Total Sell Value |
$0 |
$0 |
$70,517 |
$126,006 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
4 |
8 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ehrlich Jason |
See Remarks |
• – – |
2020-10-20 |
4 |
AS |
$76.53 |
$544,817 |
D/D |
(6,950) |
42,843 |
|
60% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-10-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
49,793 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-10-13 |
4 |
AS |
$75.00 |
$375,000 |
D/D |
(5,000) |
42,843 |
|
64% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-10-13 |
4 |
OE |
$10.29 |
$51,450 |
D/D |
5,000 |
47,843 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-10-09 |
4 |
AS |
$69.91 |
$156,819 |
D/D |
(2,200) |
42,843 |
|
68% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-10-09 |
4 |
D |
$71.25 |
$280,796 |
D/D |
(3,941) |
45,043 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-10-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
48,984 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-09-25 |
4 |
B |
$55.35 |
$2,726,182 |
I/I |
48,125 |
11,324,937 |
2.25 |
172% |
|
| Baker Julian |
Director |
– • • |
2020-09-24 |
4 |
B |
$51.41 |
$1,873,924 |
I/I |
36,020 |
11,280,001 |
2.25 |
185% |
|
| Baker Julian |
Director |
– • • |
2020-09-23 |
4 |
B |
$51.97 |
$4,826,756 |
I/I |
92,069 |
11,246,368 |
2.25 |
176% |
|
| Baker Julian |
Director |
– • • |
2020-09-22 |
4 |
B |
$49.72 |
$3,797,911 |
I/I |
74,958 |
11,160,400 |
2.25 |
164% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-09-21 |
4 |
AS |
$51.55 |
$364,182 |
D/D |
(6,950) |
33,984 |
|
174% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-09-21 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
40,934 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-09-08 |
4 |
B |
$45.88 |
$5,505,934 |
I/I |
116,295 |
11,090,409 |
2.25 |
234% |
|
| Baker Julian |
Director |
– • • |
2020-09-04 |
4 |
B |
$45.30 |
$3,869,473 |
I/I |
82,801 |
10,982,772 |
2.25 |
246% |
|
| Baker Julian |
Director |
– • • |
2020-09-03 |
4 |
B |
$46.97 |
$5,942,904 |
I/I |
123,883 |
10,905,982 |
2.25 |
234% |
|
| Baker Julian |
Director |
– • • |
2020-08-21 |
4 |
B |
$47.74 |
$6,762,056 |
I/I |
139,044 |
10,791,092 |
2.25 |
173% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-08-20 |
4 |
AS |
$46.42 |
$327,444 |
D/D |
(6,950) |
33,984 |
|
187% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-08-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
40,934 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-08-20 |
4 |
B |
$46.30 |
$2,871,156 |
I/I |
60,573 |
10,662,260 |
2.25 |
187% |
|
| Baker Julian |
Director |
– • • |
2020-08-19 |
4 |
B |
$46.99 |
$181,791 |
I/I |
3,869 |
10,606,135 |
2.25 |
213% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-07-20 |
4 |
AS |
$49.77 |
$350,526 |
D/D |
(6,950) |
33,984 |
|
167% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-07-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
40,934 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-07-02 |
4 |
OE |
$10.29 |
$27,783 |
D/D |
2,700 |
33,984 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-06-22 |
4 |
AS |
$59.35 |
$420,747 |
D/D |
(6,950) |
31,284 |
|
54% |
|
101 Records found
|
|
Page 4 of 5 |
|
|
0.07 (1.89%) 
